Thermo Fisher Scientific Human IFN-beta Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 1 publication 1 publication

ELISA (ELISA)

-

View 2 publications 2 publications

Functional Assay (Functional)

Assay-dependent

View 1 publication 1 publication

Inhibition Assays (IA)

-

View 1 publication 1 publication

In vitro Assay (IV)

-

View 92 publications 92 publications

Miscellaneous PubMed (Misc)

-

View 18 publications 18 publications

Product Specifications

Species

Human

Published species

Human, Mouse, Pig

Expression System

CHO cells

Amino acid sequence

MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN

Molecular weight

20 kDa

Class

Recombinant

Type

Protein

Purity

≥ 95% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Determined by a cytotoxicity assay using human TF-1 cells. The expected ED50 is ≤ 0.1 ng/ml, corresponding to a specific activity of ≥ 1 x 10^7 units/mg.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Product Specific Information

300-02BC-1MG will be provided as 2 x 500 µg (300-02BC-500UG).

PeproTech`s Recombinant Human IFN-beta is a 20.0 kDa protein containing 166 amino acid residues. Due to glycosylation, IFN-beta has an approximate MW of 22.3 kDa based on SDS-PAGE gel and Mass Spectrometry. *Human IFN-beta (Catalog Number 300-02BC) has replaced Human IFN-beta (Catalog Number 300-02B)

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.